Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
Colorcon
McKesson
Johnson and Johnson
Baxter

Last Updated: November 21, 2019

DrugPatentWatch Database Preview

Litigation Details for Somerset Pharmaceuticals Inc. v. Dudas (D. Del. 2007)

See Plans and Pricing

« Back to Dashboard

Small Molecule Drugs cited in Somerset Pharmaceuticals Inc. v. Dudas
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for Somerset Pharmaceuticals Inc. v. Dudas (D. Del. 2007)

Date Filed Document No. Description Snippet Link To Document
2007-05-22 1 Complaint Date of Patent: Apr. 5, 1994 5,030.619 1/1991 savannah ..................... 514/946 5,045,317 9/1991…extension to the term of U.S. Reissue Patent No. 34,579 (“the ‘579 Patent”) until August 18, 2008, or until…certain claims of the ‘579 Patent. 7. Currently, the term of the ‘579 Patent is set to expire on August…Agglication for Patent Term Extension 8. 35 U.S.C. § 156 provides that the term of a patent which claims…original expiration date of the patent to reimburse the NDA Applicant for patent life lost While going through External link to document
2007-06-11 14 Answering Brief in Opposition Dickinson, Ellzabeth Subject: RE: Vusion Patent # 4,911,932 - Eiigibiiity Letter Thanks for the efforts…Carol; Dickinson, Elizabeth Subject: Vuston Patent # 4,911,932 ~ Eligibility Letter Here's the Vusion…OB_Rx |ist. Patent Data App| Prod Patent Patent Drug Substance Drug Product Patent Use No No No Expiration… its Reissue Patent-No. 34,579 (“the ’579 patent”), which Plaintiff alleges offers patent protection for… U.S. Patent No. 7,070,808 and U.S. Patent No. 7,150,881. Plaintiff listed both of those patents in the External link to document
2007-08-02 32 Memorandum in Opposition other`patents providing protection f`or EMSAM®, namely, U.S. Patent No. 7,070,808 and U.S. Patent No. 7,150,881…of United States Reissue Patent No._ RE 34,579 (the ’579 patent). That patent is currently set to expire…extend2 the tenn of its U.S. Reissue Patent No. 34,579 (“the _’579 patent”i. Tlns is the same relief that …filed an application for-patent term extension under 35 U.S.C. § 156 (“Patent Term Extension Applicati…seeks to extend the term of`-`the ’579 patent, which offers patent protection for El\/fSAl\/l®.4 Rl74-291 External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
McKesson
Johnson and Johnson
Mallinckrodt
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.